Isofol announces the launch of new Advisory Board in connection with ASCO 2025
GOTHENBURG, Sweden, June 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company is participating […]
Corporate Information
Isofol granted Pre-IND meeting with the FDA for arfolitixorin
GOTHENBURG, Sweden, June 2, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has been
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21, 2025
GOTHENBURG, May 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (the “AGM”) today
Interview with Isofol’s CEO Petter Segelman Lindqvist on upcoming rights issue
GOTHENBURG, Sweden, May 14, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company’s CEO Petter
Notice to attend the Extraordinary General Meeting held on June 11, 2025 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, May 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical
Isofol includes first patient in a clinical phase Ib/II study of arfolitixorin
GOTHENBURG, Sweden, April 28, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the first patient has been
Notice to attend the Annual General Meeting held on May 21, 2025 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, April 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical
Isofol’s partner Solasia intends to increase investments in upcoming trials with arfolitixorin
GOTHENBURG, Sweden, April 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s Japanese development and
Isofol etablishes advisory board with leading experts
GOTHENBURG, Sweden, March 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has established
Isofol receives regulatory approval to initiate clinical study of arfolitixorin
GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in